Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after direct-acting hepatitis C therapeutics corresponded to a lower incidence rate of hepatocellular carcinoma (HCC) below the cost-effective threshold for surveillance-MedSci.cn

Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after direct-acting hepatitis C therapeutics corresponded to a lower incidence rate of hepatocellular carcinoma (HCC) below the cost-effective threshold for surveillance

Dunn, W; Koestler, D; Ni, LY; Kersey, K; Hammond, K; Chokkalingam, A; Brainard, D; Weinman, S

JOURNAL OF HEPATOLOGY, 2021; 75 (): S489

科室
- - 订阅+
  - 更多科室
工具
服务